SUNNYVALE, Calif., Oct. 28, 2020 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY), a pioneer in the robotic stereotactic
radiosurgery (SRS) field announced
today a collaboration with Brainlab, a Munich, Germany based market leader in digital
surgery and precision radiotherapy that will enhance and expand the
Accuray CyberKnife® treatment platform for the
neuro-radiosurgery market. The two companies are partnering to
provide the neuro-radiosurgery community with access to Brainlab
Elements planning software, which will provide contouring
capabilities optimized for neurosurgeons. The partners will further
strive to leverage interoperability with Snke OS, the Brainlab
health tech platform to ultimately improve the experience of those
administering and receiving radiation treatments. This
interoperability will also allow customers to add CyberKnife
treatment data via Quentry, the Brainlab patient registry platform,
and enable their participation in neuro-radiosurgery patient
registries to help improve patient outcomes.
Snke OS is the platform from Brainlab that creates the linkage
between data sources, driving comprehensive insights and analytics
with the aim to improve health tech and best practices. The
software delivers on the broader goal to create comprehensive
digital patient models that are continuously updated and managed
along the patient journey. Integration and aggregation of the
patient models in the cloud-based version of Snke OS allows for
systematic analysis and lays the foundation for digital clinical
research. The platform is being designed to facilitate adaptive
radiotherapy workflows by enabling rapid re-planning based on
dynamic updates of the digital patient model.
The CyberKnife S7TM System is a robotic, non-invasive
radiation therapy device that offers a highly precise treatment for
cancerous and benign tumors throughout the body, as well as
functional neurologic/movement disorders. It is routinely used
to treat conditions in the brain while minimizing dose to brain
tissues involved in important functions such as hearing and vision.
The CyberKnife System combines state-of-the-art robotic
architecture with fully integrated image guidance and continual,
delivery adaptation and motion synchronization, enabling the
delivery of stereotactic radiosurgery with sub-millimeter precision
and accuracy.
"The Accuray team is excited to partner with Brainlab,
recognized leaders in treatment planning, surgical navigation and
innovators in radiotherapy and radiosurgery solutions that advance
patient care," said Joshua H.
Levine, president and chief executive officer of Accuray.
"This marks an important next step in the evolution of the
CyberKnife platform by expanding the capabilities to align with the
needs of the neurosurgical community. We believe our two companies
bring powerful and complementary expertise that when combined, will
raise the bar for what can be achieved in terms of efficiency,
accuracy and precision, on behalf of neurosurgeons and their
patients."
About Accuray
Accuray Incorporated (Nasdaq: ARAY)
develops, manufactures and sells radiation therapy systems that are
intended to make cancer treatments shorter, safer, personalized and
more effective, ultimately enabling patients to live longer, better
lives. Our radiation treatment delivery systems in combination with
fully integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter
and YouTube.
Safe Harbor Statement
Statements made in this press
release that are not statements of historical fact are
forward-looking statements and are subject to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release relate, but are
not limited, to the anticipated results of Accuray's partnership
with Brainlab, the expansion of the CyberKnife platform's
capabilities, clinical applications, clinical results, patient
experiences and patient outcomes. These forward-looking statements
involve risks and uncertainties. If any of these risks or
uncertainties materialize, or if any of Accuray's assumptions prove
incorrect, actual results could differ materially from the results
expressed or implied by these forward-looking statements. These
risks and uncertainties include, but are not limited to, the effect
of the COVID-19 pandemic on the operations of Accuray and its
customers and suppliers, Accuray's ability to achieve widespread
market acceptance of its products; Accuray's ability to develop new
products or improve existing products to meet customers' needs;
Accuray's ability to anticipate or keep pace with changes in the
marketplace and the direction of technological innovation and
customer demands and such other risks identified under the heading
"Risk Factors" in Accuray's annual report on Form 10-K, filed with
the Securities and Exchange Commission (the "SEC") on August 25, 2020, and as updated periodically with
Accuray's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
Accuray assumes no obligation to update forward-looking statements
to reflect actual performance or results, changes in assumptions or
changes in other factors affecting forward-looking information,
except to the extent required by applicable securities laws.
Accordingly, investors should not put undue reliance on any
forward-looking statements.
About Brainlab
Brainlab is a digital medical
technology pioneer founded in 1989 and headquartered in
Munich. The company employs more
than 1,400 people in 18 offices around the globe. Brainlab serves
physicians, medical professionals and their patients in over 5,500
hospitals in 116 countries.
Brainlab creates software-driven medical solutions that
digitize, automate and optimize clinical workflows for
neurosurgery, spine, trauma, craniomaxillofacial (CMF), general and
vascular surgery as well as radiotherapy and radiosurgery. Core
products center around surgical navigation, radiotherapy, digital
operating room integration, and information and knowledge exchange.
The Brainlab open framework operating system will allow third
parties to develop medical applications to further advance the
field of spatial computing and mixed reality.
Brainlab is dedicated to creating an impact in healthcare. The
company connects opportunities from emerging digital technologies
to transform healthcare at scale and help improve the lives of
patients worldwide. For more information please visit Brainlab, and
follow on LinkedIn, Twitter and Facebook.
About Snke OS
Snke OS™ is a universally deployable
digital B2B platform that delivers a broad and comprehensive
healthcare operating system to power applications for third party
content providers and consumers. Fueled by AI, big data, cloud
computing, robotics and mixed reality, Snke OS delivers the
technology and infrastructure that power and advance industry-wide
digital health tech innovation.
The Snke OS team of 130 people is enabling partners across the
healthcare industry to deploy digital solutions for safer and more
efficient medical interventions. Lead fast and lead first with Snke
OS.
Accuray
Media Contact
Beth Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Investor Contact
Joe Diaz
Investor Relations, Lytham Partners
+1 (602) 889-9700
diaz@lythampartners.com
Brainlab
Debbra
Verard
Director, Marketing and Communications
+1 (708) 409-1343
debbra.verard@brainlab.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/accuray-announces-agreement-with-brainlab-to-expand-cyberknife-platform-treatment-capabilities-for-the-neuro-radiosurgery-market-301161527.html
SOURCE Accuray Incorporated